Batki S, Manfredi LB, Jacob P, Jones R; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 281 (abstract no. W.B.2397).

University of California, San Francisco, CA, USA

OBJECTIVE: To test the effectiveness of fluoxetine treatment of cocaine abuse in HIV-infected intravenous drug users (IVDUs). METHOD: Eleven HIV-infected patients participated in an open trial of fluoxetine in the treatment of cocaine dependence. Ten patients were in CDC Group IV (3 had AIDS and 7 had AIDS-related conditions), one patient was in CDC group II (asymptomatic HIV infection). Six (54%) were male, mean age was 39 years. All patients were IVDUs in methadone maintenance treatment (MMT) and met DSM-III-R criteria for cocaine and opioid dependence. Mean age of first heroin and cocaine use was 21 years and 28 years respectively. Mean daily methadone dose was 54.2 mg. Four (36%) patients used cocaine by injection, while the remaining 7 exclusively smoked cocaine. Fluoxetine was given in doses of up to 60 mg. per day for nine weeks with combined weekly group therapy. RESULTS: All patients completed the study. Fluoxetine was well tolerated. Average number of days of cocaine use by self-report between intake and week 9 decreased from 4 to 1 (p less than .001, paired t-test). Craving (range of 0-24) for cocaine decreased from 13.9 (+/- 6) to 3.5 (+/- 3) (p less than .001). Mean urine adjusted (ng/ml Cocaine per mg/ml Creatinine) cocaine levels decreased from 3145.5 ng/ml (+/- 6974.3) at intake to 128 ng/ml (+/- 254) at week 9 (p less than .05), Wilcoxon signed rank test). Mean urine adjusted (ng/ml +/- 25108.7) (p less than .05, Wilcoxon signed rank test). CD4 lymphocyte counts were obtained before and after the nine weeks of treatment in four patients. Mean CD4 was 484.5 (+/-78) before and 522.5 (+/-104) after treatment. CONCLUSION: Fluoxetine may be a well-tolerated and potentially useful agent for reducing cocaine abuse when combined with group therapy in HIV-infected IVDUs in MMT.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Centers for Disease Control and Prevention (U.S.)
• Cocaine
• Cocaine-Related Disorders
• Fluoxetine
• HIV Infections
• HIV Seropositivity
• Heroin
• Humans
• Male
• Methadone
• Opioid-Related Disorders
• Substance Abuse, Intravenous
• United States
• therapy

Other ID:

• 3239791

UI: 102193027

From Meeting Abstracts